Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Overweight at Cantor Fitzgerald
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) was upgraded by research analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The brokerage presently has a $10.00 price objective on the stock. Cantor Fitzgerald’s price objective points to a potential […]
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) was upgraded by research analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The brokerage presently has a $10.00 price objective on the stock. Cantor Fitzgerald’s price objective points to a potential […]
